Change in U.S. list and net drug prices 2022 by manufacturer
In 2022, the average net price in the U.S. of GlaxoSmithKline's brand-name product portfolio increased by 1.4 percent, while the average net price of Novo Nordisk's portfolio decreased by 10.5 percent. This statistic illusrates the percentage change in list and net pharmaceutical product portfolio prices in the U.S., by manufacturer.